TY - JOUR
T1 - Recommendations for the detection and diagnosis of Niemann-Pick disease type C
T2 - An update
AU - Patterson, Marc C.
AU - Clayton, Peter
AU - Gissen, Paul
AU - Anheim, Mathieu
AU - Bauer, Peter
AU - Bonnot, Olivier
AU - Dardis, Andrea
AU - Dionisi-Vici, Carlo
AU - Klünemann, Hans Hermann
AU - Latour, Philippe
AU - Lourenço, Charles M.
AU - Ory, Daniel S.
AU - Parker, Alasdair
AU - Pocovi, Miguel
AU - Strupp, Michael
AU - Vanier, Marie T.
AU - Walterfang, Mark
AU - Marquardt, Thorsten
N1 - Publisher Copyright:
© 2017 American Academy of Neurology.
PY - 2017
Y1 - 2017
N2 - Purpose of review: Niemann-Pick disease type C (NP-C) is a neurovisceral disorder that may be more prevalent than earlier estimates. Diagnosis of NP-C is often delayed; a key aim for clinical practice is to reduce this delay. Recently, substantial progress has been made in the field of NP-C screening and diagnosis, justifying an update to the existing recommendations for clinical practice. Recent findings: New biomarker profiling and genetic analysis technologies are included as first-line diagnostic tests for NP-C. Most diagnoses can now be confirmed by combination of biomarker and genetic analyses. Filipin staining may facilitate diagnosis in uncertain cases. Recommendations are provided for psychiatrists, neuro-ophthalmologists, and radiologists, and on screening within specific at-risk patient cohorts. The NP-C diagnostic algorithm has been updated and simplified. Summary: This publication provides expert recommendations for clinicians who may see patients presenting with the signs and symptoms of NP-C, including general practitioners, pediatricians, neurologists, and psychiatrists.
AB - Purpose of review: Niemann-Pick disease type C (NP-C) is a neurovisceral disorder that may be more prevalent than earlier estimates. Diagnosis of NP-C is often delayed; a key aim for clinical practice is to reduce this delay. Recently, substantial progress has been made in the field of NP-C screening and diagnosis, justifying an update to the existing recommendations for clinical practice. Recent findings: New biomarker profiling and genetic analysis technologies are included as first-line diagnostic tests for NP-C. Most diagnoses can now be confirmed by combination of biomarker and genetic analyses. Filipin staining may facilitate diagnosis in uncertain cases. Recommendations are provided for psychiatrists, neuro-ophthalmologists, and radiologists, and on screening within specific at-risk patient cohorts. The NP-C diagnostic algorithm has been updated and simplified. Summary: This publication provides expert recommendations for clinicians who may see patients presenting with the signs and symptoms of NP-C, including general practitioners, pediatricians, neurologists, and psychiatrists.
UR - http://www.scopus.com/inward/record.url?scp=85042165675&partnerID=8YFLogxK
U2 - 10.1212/CPJ.0000000000000399
DO - 10.1212/CPJ.0000000000000399
M3 - Review article
C2 - 29431164
AN - SCOPUS:85042165675
SN - 2163-0402
VL - 7
SP - 499
EP - 511
JO - Neurology: Clinical Practice
JF - Neurology: Clinical Practice
IS - 6
ER -